Orthofix International | OFIX - Selling And Administration Expenses


Orthofix International reported $130.35M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 84.55M 6.21M Mar/2026
Dexcom USD 349.7M 49.8M Mar/2026
EDAP TMS EUR 8.81M 1.57M Sep/2025
Globus Medical USD 297.77M 20.7M Mar/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 317.2M 14.2M Mar/2026
Integra LifeSciences USD 178.24M 21.79M Mar/2026
J&J USD 6.03B 719M Mar/2026
Medtronic 2.97B 159M Sep/2025
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Plus Therapeutics USD 3.49M 559K Dec/2025
Smith & Nephew USD 1.42B 65M Dec/2025
STAAR Surgical USD 38.64M 299K Mar/2026
Stryker USD 2.15B 17M Mar/2026
Surmodics USD 11.4M 3.18M Jun/2025
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026